Literature DB >> 16555274

Respiratory syncytial virus infection in a murine model of cystic fibrosis.

Giuseppe N Colasurdo1, Jason J Fullmer, Okan Elidemir, Constance Atkins, Amir M Khan, James M Stark.   

Abstract

Viral respiratory infections play an important role in the development and progression of pulmonary disease in cystic fibrosis (CF). The CF mouse model provides a tool to examine the relationship between the cystic fibrosis transmembrane conductance regulator (CFTR) defect and lung disease. This work investigates the cellular response to a common viral pathogen, respiratory syncytial virus (RSV) in the lung of CF mice. RSV was administered by intranasal inoculation of CFTR(tm1Unc)-Tg(FABPCFTR)1Jaw/J (CFTR-/-) and control mice. At day 5 post infection, viral titers, bronchoalveolar fluid nitrate levels (BALF) cell and differential counts, histology and studies on airway mechanics were performed. CFTR-/- mice had an impaired ability to clear RSV. This was associated with an exaggerated inflammatory response (increased lymphocytes and neutrophils) in BALF of RSV-infected CFTR-/- mice and a decreased ability to generate nitric oxide (NO) (measured as BAL nitrate). Lung histopathology of RSV-infected CFTR-/- mice demonstrated increased inflammation compared to RSV (-) CFTR-/- and control mice (regardless of RSV treatment). The airway response to methacholine was increased by RSV infection in CF mice when compared to controls. The CFTR-/- mouse exhibits an aberrant response to RSV infection. This model should be useful in providing further mechanistic information on the biology of respiratory viruses in mammalian models, and provide new insights into the pathogenesis of airway inflammation in patients with CF. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16555274     DOI: 10.1002/jmv.20589

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  15 in total

1.  Respiratory syncytial virus pathophysiology and affect of palivizumab in special populations: cystic fibrosis and immunosuppression.

Authors:  Michael E Speer
Journal:  J Pediatr Pharmacol Ther       Date:  2011-04

Review 2.  Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.

Authors:  Karen A Robinson; Olaide A Odelola; Ian J Saldanha
Journal:  Cochrane Database Syst Rev       Date:  2016-07-20

3.  Cholesterol modulates CFTR confinement in the plasma membrane of primary epithelial cells.

Authors:  Asmahan Abu-Arish; Elvis Pandzic; Julie Goepp; Elizabeth Matthes; John W Hanrahan; Paul W Wiseman
Journal:  Biophys J       Date:  2015-07-07       Impact factor: 4.033

4.  Viral interference and the live-attenuated intranasal influenza vaccine: Results from a pediatric cohort with cystic fibrosis.

Authors:  Constantina Boikos; Jesse Papenburg; Christine Martineau; Lawrence Joseph; David Scheifele; Mark Chilvers; Larry C Lands; Gaston De Serres; Caroline Quach
Journal:  Hum Vaccin Immunother       Date:  2017-03-08       Impact factor: 3.452

5.  Low sphingosine-1-phosphate impairs lung dendritic cells in cystic fibrosis.

Authors:  Yaqin Xu; Anja Krause; Maria Limberis; Tilla S Worgall; Stefan Worgall
Journal:  Am J Respir Cell Mol Biol       Date:  2012-12-13       Impact factor: 6.914

6.  Airway Surface Liquid Has Innate Antiviral Activity That Is Reduced in Cystic Fibrosis.

Authors:  Abigail R Berkebile; Jennifer A Bartlett; Mahmoud Abou Alaiwa; Steven M Varga; Ultan F Power; Paul B McCray
Journal:  Am J Respir Cell Mol Biol       Date:  2020-01       Impact factor: 6.914

7.  Genomewide association analysis of respiratory syncytial virus infection in mice.

Authors:  James M Stark; M Michael Barmada; Abby V Winterberg; Nilanjana Majumber; William J Gibbons; Marilyn A Stark; Maureen A Sartor; Mario Medvedovic; Jay Kolls; Kiflai Bein; Beena Mailaparambil; Marcus Krueger; Andrea Heinzmann; George D Leikauf; Daniel R Prows
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

8.  Respiratory syncytial virus infection reduces lung inflammation and fibrosis in mice exposed to vanadium pentoxide.

Authors:  Elizabeth A Turpin; Aurita Antao-Menezes; Mark F Cesta; James B Mangum; Duncan G Wallace; Edilberto Bermudez; James C Bonner
Journal:  Respir Res       Date:  2010-02-22

9.  Persistent of respiratory syncytial virus in human dendritic cells and influence of nitric oxide.

Authors:  L Hobson; M L Everard
Journal:  Clin Exp Immunol       Date:  2007-12-06       Impact factor: 4.330

10.  H5N1 Virus Hemagglutinin Inhibition of cAMP-Dependent CFTR via TLR4-Mediated Janus Tyrosine Kinase 3 Activation Exacerbates Lung Inflammation.

Authors:  Ke Cao; Minhui Chen; Xiang Jie; Yansheng Wang; Qiasheng Li; Jun Xu
Journal:  Mol Med       Date:  2015-01-12       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.